Solventum (NYSE:SOLV) Trading Down 6.7% – Time to Sell?

Solventum Corporation (NYSE:SOLV) traded down 6.7% on Tuesday . The stock traded as low as $79.74 and last traded at $79.9350. 1,050,631 shares traded hands during trading, an increase of 9% from the average session volume of 964,026 shares. The stock had previously closed at $85.69.

Analyst Ratings Changes

Several analysts have recently issued reports on SOLV shares. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, December 2nd. UBS Group restated a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Finally, Piper Sandler restated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Solventum has an average rating of “Hold” and an average target price of $88.64.

Solventum Price Performance

The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The company has a market capitalization of $13.88 billion, a P/E ratio of 9.22, a P/E/G ratio of 8.57 and a beta of 0.34. The firm’s fifty day moving average is $80.17 and its 200 day moving average is $75.52.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same period in the prior year, the business posted $1.64 earnings per share. The company’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its board has approved a share buyback program on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Solventum

Large investors have recently added to or reduced their stakes in the stock. Hilltop National Bank grew its stake in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new stake in Solventum during the 3rd quarter valued at $25,000. Deseret Mutual Benefit Administrators grew its position in shares of Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares in the last quarter. CYBER HORNET ETFs LLC bought a new stake in shares of Solventum in the second quarter valued at about $28,000. Finally, Barrett & Company Inc. lifted its stake in Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.